Pre-market hot trades in US stocks: Galaxy Payroll pre-market down 15.61%; United Microelectronics pre-market up 14.09%

Pre-market Hot Trades in US Stocks Galaxy Payroll, down 15.61% in pre-market trading, has no significant recent news. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. United Microelectronics, up 14.09% in pre-market trading. Based on recent news, On January 19, United Microelectronics benefited from strong demand for 28 and 22 nanometers, with an expected 16.32% growth in after-tax earnings per share this year, and a target price of 71 yuan, driving a significant increase in stock price. Source: Zhitong Finance On January 20, United Microelectronics obtained authorization for imec's advanced silicon photonics process technology, accelerating the development of the 12-inch silicon photonics platform, attracting new customer collaborations, and boosting market confidence. Source: Zhitong Finance On January 19, IDC estimated that the global semiconductor market will grow by 11% in 2026, with wafer foundry growing by 20% annually. As a leading manufacturer in mature processes, United Microelectronics stands to benefit significantly. Source: Zhitong Finance The semiconductor industry shows strong demand, and the market outlook is positive. Top Gainers in Pre-market US Stocks INVO Fertility, up 405.91% in pre-market trading, has no significant recent news. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Icon Energy, up 140.21% in pre-market trading, has no significant recent news. The trading is active, with clear capital flow. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. RAPT, up 63.42% in pre-market trading. Based on recent key news: On January 20, GSK announced the acquisition of RAPT Therapeutics for $2.2 billion, driving RAPT's stock price up 63.42% in pre-market trading. This acquisition will give GSK global rights to RAPT's experimental food allergy drug ozureprubart, excluding mainland China, Macau, Taiwan, and Hong Kong. This move expands GSK's respiratory, immunology, and inflammation product lines. Source: Reuters On January 20, GSK plans to acquire RAPT at a price of $58 per share, which represents a significant premium over RAPT's last closing price. This transaction is expected to be completed in the first quarter of 2026, further driving RAPT's stock price up. Source: MT Newswires On January 20, GSK's Chief Scientific Officer Tony Wood stated that ozureprubart is expected to become a best-in-class treatment option, providing sustained protection every 12 weeks, aligning with GSK's strategic goals. This news has enhanced market confidence in RAPT. Source: Dow Jones Newswires The biotech industry is active in mergers and acquisitions, with significant capital inflow